Pacific Biosciences Of California Share Price Today
(NASDAQ: PACB)

Name: Pacific Biosciences Of California Share Price Today (NASDAQ: PACB) - Pacific Biosciences Of California Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Pacific Biosciences Of California share price is $1.44 & ₹125.42 as on 5 Feb 2025, 2.30 'hrs' IST

$1.44

▲

-0.02

(-1.37%)

Market is closed - opens 8 PM, 05 Feb 2025

View live Pacific Biosciences Of California share price in Dollar and Rupees. Guide to invest in Pacific Biosciences Of California stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Pacific Biosciences Of California, along with analyst recommendations, forecasts, and comprehensive financials.

Pacific Biosciences Of California share price movements

Today's Low: $1.39
Today's High: $1.47
$1.44
3.47%
Downside
Day's Volatility :5.12%
Upside
1.71%
52 Weeks Low: $1.16
52 Weeks High: $6.83
$1.44
19.44%
Downside
52 Weeks Volatility :83.02%
Upside
78.92%

Pacific Biosciences Of California (PACB) Returns

Period	Pacific Biosciences Of California, Inc.	Sector (Health Care)	Index (Russel 2000)
3 Months	-45.66%	-0.5%	0.0%
6 Months	-5.88%	0.1%	0.0%
1 Year	-78.08%	3.2%	0.0%
3 Years	-86.92%	11.1%	-11.7%

Pacific Biosciences Of California (PACB) Key Statistics

in dollars & INR

Previous Close	$1.46
Open	$1.47
Today's High	$1.465
Today's Low	$1.39
Market Capitalization	$423.8M
Today's Volume	$11.1M
52 Week High	$6.83
52 Week Low	$1.16
Revenue TTM	$173.1M
EBITDA	$-242.9M
Earnings Per Share (EPS)	$-1.46
Profit Margin	-227.69%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-64.8%

How to invest in Pacific Biosciences Of California Stock (PACB) from India?

It is very easy for Indian residents to invest directly in Pacific Biosciences Of California from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Pacific Biosciences Of California stock in both Indian Rupees (INR) and US Dollars (USD). Search for Pacific Biosciences Of California or PACB on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Pacific Biosciences Of California or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Pacific Biosciences Of California shares which would translate to 0.605 fractional shares of Pacific Biosciences Of California as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Pacific Biosciences Of California, in just a few clicks!

Returns in Pacific Biosciences Of California (PACB) for Indian investors in Rupees

The Pacific Biosciences Of California stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

Pacific Biosciences Of California investment value today

Current value as on today

₹26,821

Returns

₹73,179

(-73.18%)

Returns from Pacific Biosciences Of California Stock

₹78,082 (-78.08%)

Dollar Returns

₹4,903 (+4.9%)

Indian investors sentiment towards Pacific Biosciences Of California (PACB)

32.22%

Period: Jan 5, 2025 to Feb 4, 2025. Change in 30 Days versus previous period

Investment in Pacific Biosciences Of California Shares from India has grown by 32.22% over the past 30 days, indicating increased transactional activity.

35%

Period: Jan 5, 2025 to Feb 4, 2025. Change in 30 Days versus previous period

Search interest for Pacific Biosciences Of California Stock from India on INDmoney has increased by 35% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Pacific Biosciences Of California

ARK Investment Management LLC
11.35%
Madrone Advisors LLC
7.95%
BlackRock Inc
7.90%
Edmond de Rothschild Holding S.A.
6.90%
Vanguard Group Inc
5.99%
Nikko Asset Management Americas Inc
4.03%

Analyst Recommendation on Pacific Biosciences Of California

Buy

55%Buy

45%Hold

0%Sell

Based on 20 Wall street analysts offering stock ratings for Pacific Biosciences Of California(by analysts ranked 0 to 5 stars)

Based on 20 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Pacific Biosciences Of California Stock (PACB)

What analysts predicted

Upside of 106.89%

Target:

$2.98

Current:

$1.44

Insights on Pacific Biosciences Of California Stock (Ticker Symbol: PACB)

Price Movement
In the last 7 days, PACB stock has moved down by -7.7%
Increasing Revenue
Revenue is up for the last 2 quarters, 36.01M → 39.96M (in $), with an average increase of 9.9% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, -173.31M → -60.72M (in $), with an average increase of 185.4% per quarter
PACB vs BSX (1 yr)
In the last 1 year, Boston Scientific Corp. has given 60.6% return, outperforming this stock by 138.2%
PACB vs BSX (3 yr)
In the last 3 years, Boston Scientific Corp. has given 142.1% return, outperforming this stock by 228.8%
Price to Sales
ForPACB every $1 of sales, investors are willing to pay $2.3, whereas for Boston Scientific Corp., the investors are paying $9.6 for every $1 of sales.

PACB Pacific Biosciences Of California Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$78.6M	↓ 15.88%
Net Income	$-102.6M	↑ 11.25%
Net Profit Margin	-130.44%	↓ 31.81%

	FY19	Y/Y Change
Revenue	$90.9M	↑ 15.6%
Net Income	$-77.8M	↓ 24.12%
Net Profit Margin	-85.62%	↑ 44.82%

	FY20	Y/Y Change
Revenue	$78.9M	↓ 13.2%
Net Income	$29.4M	↓ 137.78%
Net Profit Margin	37.27%	↑ 122.89%

	FY21	Y/Y Change
Revenue	$130.5M	↑ 65.43%
Net Income	$-181.2M	↓ 716.34%
Net Profit Margin	-138.85%	↓ 176.12%

	FY22	Y/Y Change
Revenue	$128.3M	↓ 1.69%
Net Income	$-296.9M	↑ 63.85%
Net Profit Margin	-231.43%	↓ 92.58%

	FY23	Y/Y Change
Revenue	$200.5M	↑ 56.29%
Net Income	$-306.7M	↑ 3.3%
Net Profit Margin	-152.97%	↑ 78.46%

	Q2 FY23	Q/Q Change
Revenue	$47.6M	↑ 22.3%
Net Income	$-69.8M	↓ 13.94%
Net Profit Margin	-146.79%	↑ 61.82%

	Q3 FY23	Q/Q Change
Revenue	$55.7M	↑ 17.06%
Net Income	$-66.9M	↓ 4.24%
Net Profit Margin	-120.07%	↑ 26.72%

	Q4 FY23	Q/Q Change
Revenue	$58.4M	↑ 4.79%
Net Income	$-82.0M	↑ 22.65%
Net Profit Margin	-140.55%	↓ 20.48%

	Q1 FY24	Q/Q Change
Revenue	$38.8M	↓ 33.5%
Net Income	$-78.2M	↓ 4.68%
Net Profit Margin	-201.44%	↓ 60.89%

	Q2 FY24	Q/Q Change
Revenue	$36.0M	↓ 7.21%
Net Income	$-173.3M	↑ 121.7%
Net Profit Margin	-481.27%	↓ 279.83%

	Q3 FY24	Q/Q Change
Revenue	$40.0M	↑ 10.98%
Net Income	$-60.7M	↓ 64.96%
Net Profit Margin	-151.94%	↑ 329.33%

	FY18	Y/Y Change
Profit	$25.1M	↓ 27.59%

	FY19	Y/Y Change
Profit	$34.6M	↑ 37.77%

	FY20	Y/Y Change
Profit	$32.6M	↓ 5.81%

	FY21	Y/Y Change
Profit	$58.9M	↑ 80.74%

	FY22	Y/Y Change
Profit	$49.0M	↓ 16.69%

	FY23	Y/Y Change
Profit	$52.8M	↑ 7.64%

	Q2 FY23	Q/Q Change
Profit	$15.5M	↑ 59.27%

	Q3 FY23	Q/Q Change
Profit	$17.9M	↑ 15.16%

	Q4 FY23	Q/Q Change
Profit	$11.0M	↓ 38.53%

	Q1 FY24	Q/Q Change
Profit	$4.4M	↓ 59.75%

	Q2 FY24	Q/Q Change
Profit	$5.9M	↑ 34.07%

	Q3 FY24	Q/Q Change
Profit	$10.0M	↑ 68.47%

	FY18	Y/Y Change
Operating Cash Flow	$-66.4M	↓ 1.61%
Investing Cash Flow	$-38.4M	↑ 2379.99%
Financing Cash Flow	$107.2M	↑ 55.77%

	FY19	Y/Y Change
Operating Cash Flow	$-78.3M	↑ 17.89%
Investing Cash Flow	$62.0M	↓ 261.52%
Financing Cash Flow	$26.5M	↓ 75.23%

	FY20	Y/Y Change
Operating Cash Flow	$19.5M	↓ 124.9%
Investing Cash Flow	$-219.3M	↓ 453.48%
Financing Cash Flow	$251.8M	↑ 848.62%

	FY21	Y/Y Change
Operating Cash Flow	$-111.2M	↓ 670.07%
Investing Cash Flow	$-678.5M	↑ 209.38%
Financing Cash Flow	$1.2B	↑ 364.42%

	FY22	Y/Y Change
Operating Cash Flow	$-263.2M	↑ 136.74%
Investing Cash Flow	$116.1M	↓ 117.11%
Financing Cash Flow	$9.6M	↓ 99.18%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$-41.7M	↓ 55.92%
Investing Cash Flow	$-98.6M	↑ 35.89%
Financing Cash Flow	$-4.7M	↓ 102.41%

Pacific Biosciences Of California Technicals Summary

Sell

Neutral

Buy

Pacific Biosciences Of California is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Pacific Biosciences Of California (PACB) Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Pacific Biosciences Of California, Inc.	-27.64%	-5.88%	-78.08%	-86.92%	-68.18%
Medtronic Plc	13.94%	12.18%	3.68%	-10.8%	-23.52%
Edwards Lifesciences Corp.	-3.01%	16.8%	-19.17%	-35.81%	-7.93%
Boston Scientific Corp.	13.42%	40.34%	59.81%	141.3%	145.41%
Stryker Corporation	8.59%	22.78%	15.49%	58.1%	82.67%
Abbott Laboratories	14.21%	17.43%	13.25%	0.82%	46.92%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Pacific Biosciences Of California, Inc.	NA	NA	-0.17	-0.81	-0.65	-0.11	NA	1.66
Medtronic Plc	27.69	27.69	1.55	5.45	0.08	0.04	0.03	38.29
Edwards Lifesciences Corp.	27.54	27.54	6.55	2.55	0.19	0.11	NA	16.18
Boston Scientific Corp.	85.18	85.18	1.86	2.46	0.09	0.05	NA	14.05
Stryker Corporation	50.47	50.47	2.73	13.51	0.19	0.07	0.01	52.86
Abbott Laboratories	16.81	16.81	2.3	5.15	0.15	0.06	0.02	22.94

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Pacific Biosciences Of California, Inc.	Buy	$423.8M	-68.18%	NA	-227.69%
Medtronic Plc	Buy	$116.1B	-23.52%	27.69	12.06%
Edwards Lifesciences Corp.	Buy	$42.1B	-7.93%	27.54	65.86%
Boston Scientific Corp.	Buy	$151.9B	145.41%	85.18	11.26%
Stryker Corporation	Buy	$149.1B	82.67%	50.47	16.34%
Abbott Laboratories	Buy	$222.8B	46.92%	16.81	13.99%

About Pacific Biosciences Of California

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, it provides revio system + sequel systems which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. The company serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. It markets its products through a sales force and distribution partners in Asia, Australia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.

Organization	Pacific Biosciences Of California
Employees	796
CEO	Mr. Christian O. Henry M.B.A.
Industry	Health Technology

Management People of Pacific Biosciences Of California

Name	Title
Mr. Christian O. Henry M.B.A.	President, CEO, Interim CFO & Director
Dr. Stephen Turner Ph.D.	Co-Founder
Dr. Brett Atkins J.D., Ph.D.	General Counsel & Corporate Secretary
Ms. Natalie Welch	Chief People Officer

Important FAQs about investing in PACB Stock from India :

What is Pacific Biosciences Of California share price today?

Pacific Biosciences Of California share price today stands at $1.44, Open: $1.47 ; Previous Close: $1.46 ; High: $1.47 ; Low: $1.39 ; 52 Week High: $6.83 ; 52 Week Low: $1.16.

The stock opens at $1.47, after a previous close of $1.46. The stock reached a daily high of $1.47 and a low of $1.39, with a 52-week high of $6.83 and a 52-week low of $1.16.

Can Indians buy Pacific Biosciences Of California shares?

Yes, Indians can invest in the Pacific Biosciences Of California (PACB) from India.

With INDmoney, you can buy Pacific Biosciences Of California at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Pacific Biosciences Of California at zero transaction cost.

How can I buy Pacific Biosciences Of California shares from India?

It is very easy to buy Pacific Biosciences Of California from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Pacific Biosciences Of California (PACB) be purchased?

Yes, you can buy fractional shares of Pacific Biosciences Of California with INDmoney app.

What are the documents required to start investing in Pacific Biosciences Of California stocks?

To start investing in Pacific Biosciences Of California, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.